Navigation Links
Cardiome And Astellas Announce Positive Results From ACT 2 Trial

icensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent eve
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cardiome And Astellas Announce Positive Results From ACT Trial
(Date:1/15/2014)... GRAND RAPIDS, Mich. , Jan. 15, 2014 As ... of the flu virus, select Meijer pharmacies in ... and strep throat to eligible patients, enabling Meijer pharmacists to ... under strict protocol set by a physician participating in the ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Speakers Group (WWSG) , an innovative leader transforming the ... is proud to announce its exclusive representation of ... Human Services Secretary, EPA Administrator and three-term governor of ... in both the private and public sectors, Governor Leavitt ...
... 19 Accium BioSciences, a leading provider of bioanalytical ... today new pricing for its AMS measurement service at ... $115 per sample. The new pricing includes sample graphitization ... expert bioanalytical and quality assurance services at competitive rates. ...
Cached Medicine Technology:Governor Michael O. Leavitt, Former HHS Secretary and EPA Administrator, Selects WorldWide Speakers Group for Exclusive Representation 2Accium BioSciences Announces $99 Sample Pricing for Its Accelerator Mass Spectrometry (AMS) Measurement Service 2
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
(Date:4/17/2014)... YORK (17 April 2014) Population Council scientists and their ... safe, stable, and can prevent the transmission of multiple ... rectum in animals: HIV, herpes simplex virus 2 (HSV-2), ... the first data that the gel is effective against ... efficacy in the vagina against all three viruses of ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... risk of type 2 diabetesPORT ST. LUCIE, Fla., March 24 ... Diabetes Association urges all Americans to learn about type 2 ... educate the public, the American Diabetes Association and one of ... up to provide an online video that explains the symptoms ...
... Offers New Option for Adult Patients Suffering From ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: ... Food and Drug Administration (FDA) approved TYGACIL(R) (tigecycline), ... bacterial pneumonia (CABP) caused by susceptible strains of ...
... drives Victoria,s Secret Fashion Show and Armani Exchange model ... a cureHOLLYWOOD, Fla., March 24 Brazilian supermodel Izabel ... Ambassador for the Diabetes Research Institute Foundation, the nonprofit ... at the world-renowned Diabetes Research Institute (DRI) at the ...
... Israel, Iran, Saudi Arabia, Kuwait, the United Arab Emirates ... in Indianapolis April 1 and 2 for the First ... , A unique event, this conference will bring together ... foster collaboration between physicians from Western and Middle Eastern ...
... laser surgeon in Beverly Hills, appeared on The Doctors TV Show, ... the most comprehensive center specializing in laser technology and non-invasive aesthetic ... ... Beverly Hills, CA (PRWEB) March 24, 2009 -- Dr. Simon ...
... California is making health care easier and more accessible ... Proveedor Medico , the Spanish version of its existing English ... allows all visitors - even if they,re not yet Blue ... doctors and hospitals to help them make more informed decisions ...
Cached Medicine News:Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 2Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 3Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 4Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 2Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 3Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 4Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 5Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 6Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 7Health News:Supermodel Izabel Goulart Partners With Diabetes Research Institute Foundation as International Ambassador 2Health News:Supermodel Izabel Goulart Partners With Diabetes Research Institute Foundation as International Ambassador 3Health News:Dr. Simon Ourian, Pioneer Laser Surgeon, Appears on The Doctors TV Show 2Health News:Dr. Simon Ourian, Pioneer Laser Surgeon, Appears on The Doctors TV Show 3Health News:Dr. Simon Ourian, Pioneer Laser Surgeon, Appears on The Doctors TV Show 4Health News:Blue Shield of California Launches Online Spanish-Language Service to Help Members Choose a Medical Provider 2Health News:Blue Shield of California Launches Online Spanish-Language Service to Help Members Choose a Medical Provider 3
... The Bayer Immuno 1 provides ... immunoassay instrument with over 50 ... endocrinology, tumor marker, therapeutic drug, ... can be performed on a ...
... The new Synchron LXi 725 clinical ... with highly accurate immunoassay testing capabilities, ... handling on a single platform. After ... automatically repeated for optimal quality assurance. ...
...
...
Medicine Products: